SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3qd2'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MOG_A_RBFA200_1 (DODECIN)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	3 / 3	PHE B 589 TRP B 654 GLU B 656	None	1.12A	1mogA-3qd2B: undetectable	1mogA-3qd2B: 13.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1T03_P_TFOP822_1 (POL POLYPROTEIN SYNTHETIC OLIGONUCLEOTIDE PRIMER)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 7	MET B 945 ASP B 946 ASP B 947 HIS B 914	None	1.39A	1t03A-3qd2B: undetectable	1t03A-3qd2B: 20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	ALA B 616 GLU B 635 LEU B 639 CYH B 889 HIS B 933 GLY B 952	None	0.77A	1uwhA-3qd2B: 21.8	1uwhA-3qd2B: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	ALA B 616 GLU B 635 LEU B 639 HIS B 933 GLY B 952 PHE B 942	None	1.42A	1uwhA-3qd2B: 21.8	1uwhA-3qd2B: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	ALA B 616 LYS B 618 GLU B 635 LEU B 639 CYH B 889 HIS B 933 GLY B 952	None	0.76A	1uwhB-3qd2B: 21.7	1uwhB-3qd2B: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 GLU B 635 CYH B 889 HIS B 933 GLY B 952	None	0.76A	1uwjA-3qd2B: 21.5	1uwjA-3qd2B: 25.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 GLU B 635 CYH B 889 HIS B 933 GLY B 952	None	0.75A	1uwjB-3qd2B: 21.6	1uwjB-3qd2B: 25.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XDK_B_9CRB600_1 (RETINOIC ACID RECEPTOR, BETA)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 922 LEU B1008 ILE B1069 ILE B1070 LEU B 936	None	1.20A	1xdkB-3qd2B: undetectable	1xdkB-3qd2B: 21.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HC4_A_VDXA525_2 (VITAMIN D RECEPTOR)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 7	LEU B1015 LEU B1012 ILE B1005 ARG B1063	None	1.14A	2hc4A-3qd2B: undetectable	2hc4A-3qd2B: 23.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2J9D_A_ACTA1117_0 (HYPOTHETICAL NITROGEN REGULATORY PII-LIKE PROTEIN MJ0059)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	3 / 3	ASP B 906 ARG B 907 ARG B 901	None	1.10A	2j9dA-3qd2B: 2.7 2j9dC-3qd2B: undetectable	2j9dA-3qd2B: 19.02 2j9dC-3qd2B: 19.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2VAV_F_CSCF1383_2 (ACETYL-COA--DEACETYL CEPHALOSPORIN C ACETYLTRANSFERASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	3 / 3	LEU B 894 MET B 898 MET B 595	None	0.95A	2vavF-3qd2B: 2.7	2vavF-3qd2B: 20.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XYT_D_TC9D1206_2 (SOLUBLE ACETYLCHOLINE RECEPTOR)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 8	TYR B 883 GLN B 885 ILE B 617 SER B 583	None	1.01A	2xytE-3qd2B: undetectable	2xytE-3qd2B: 21.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XYT_G_TC9G1206_2 (SOLUBLE ACETYLCHOLINE RECEPTOR)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 8	TYR B 883 GLN B 885 ILE B 617 SER B 583	None	1.05A	2xytH-3qd2B: undetectable	2xytH-3qd2B: 21.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XYT_H_TC9H1206_2 (SOLUBLE ACETYLCHOLINE RECEPTOR)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 7	TYR B 883 GLN B 885 ILE B 617 SER B 583	None	1.04A	2xytI-3qd2B: undetectable	2xytI-3qd2B: 21.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEC_A_STIA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 616 LYS B 618 GLU B 635 LEU B 639 LEU B 888	None	0.52A	3hecA-3qd2B: 21.1	3hecA-3qd2B: 25.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 6	VAL B 603 LYS B 618 VAL B 648 ILE B 884	None	0.70A	3mssD-3qd2B: 21.3	3mssD-3qd2B: 24.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 955	None	0.90A	3og7A-3qd2B: 22.3	3og7A-3qd2B: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 PHE B 954	None	0.77A	3og7A-3qd2B: 22.3	3og7A-3qd2B: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 LYS B 618 LEU B 639 PHE B 942 PHE B 954	None	0.89A	3og7A-3qd2B: 22.3	3og7A-3qd2B: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4I41_A_MIXA500_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	VAL B 603 ALA B 616 ASP B 896 ASP B 935 LYS B 937 ASN B 940 ASP B 953	None	0.70A	4i41A-3qd2B: 24.9	4i41A-3qd2B: 25.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IK6_B_LURB201_1 (TRANSTHYRETIN)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 8	MET B 886 LEU B 882 ALA B 653 LEU B 655	None	0.82A	4ik6B-3qd2B: undetectable	4ik6B-3qd2B: 18.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OJB_A_198A1001_2 (ANDROGEN RECEPTOR)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 7	LEU B1012 ILE B1028 ILE B1029 VAL B1032	None	0.78A	4ojbA-3qd2B: undetectable	4ojbA-3qd2B: 22.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QMS_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 11	ALA B 616 LYS B 618 GLU B 635 ILE B 884 MET B 886 ASP B 953	None	0.75A	4qmsA-3qd2B: 25.8	4qmsA-3qd2B: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QOP_D_HQED503_1 (CATALASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 9	ILE B 617 PRO B 591 GLN B 885 TYR B 615 ASP B 611	None	1.46A	4qopD-3qd2B: 0.0	4qopD-3qd2B: 18.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 LYS B 618 GLU B 635 CYH B 889 GLY B 952	None	0.78A	4r7iA-3qd2B: 20.5	4r7iA-3qd2B: 25.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 616 LYS B 618 ILE B 884 PHE B 942 GLY B 952	None	0.52A	4rzvA-3qd2B: 22.3	4rzvA-3qd2B: 25.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 616 LYS B 618 PHE B 942 GLY B 952 PHE B 954	None	0.91A	4rzvA-3qd2B: 22.3	4rzvA-3qd2B: 25.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 952 GLY B 955	None	1.26A	4rzvB-3qd2B: 22.3	4rzvB-3qd2B: 25.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 952 PHE B 954	None	1.02A	4rzvB-3qd2B: 22.3	4rzvB-3qd2B: 25.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 952 ASP B 953 PHE B 954	None	0.71A	4xv2A-3qd2B: 22.7	4xv2A-3qd2B: 24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	VAL B 603 ALA B 616 CYH B 889 PHE B 942 GLY B 952 ASP B 953 PHE B 954	None	0.75A	4xv2A-3qd2B: 22.7	4xv2A-3qd2B: 24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 952 ASP B 953 PHE B 954	None	0.70A	4xv2B-3qd2B: 22.7	4xv2B-3qd2B: 24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	ALA B 616 LYS B 618 LEU B 639 PHE B 942 GLY B 952 ASP B 953 PHE B 954	None	0.83A	4xv2B-3qd2B: 22.7	4xv2B-3qd2B: 24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 952 PHE B 954	None	0.81A	5cswA-3qd2B: 22.4	5cswA-3qd2B: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 LYS B 618 LEU B 639 PHE B 942 PHE B 954	None	0.98A	5cswA-3qd2B: 22.4	5cswA-3qd2B: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	7 / 12	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 952 PHE B 954	None	0.84A	5cswB-3qd2B: 22.4	5cswB-3qd2B: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 ILE B 884 LEU B 888 GLY B 952 ASP B 953	None	0.69A	5h2uB-3qd2B: 16.1	5h2uB-3qd2B: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 ILE B 884 LEU B 888 GLY B 952 ASP B 953	None	0.66A	5h2uD-3qd2B: 21.8	5h2uD-3qd2B: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	VAL B 603 ALA B 616 LYS B 618 ILE B 884 ASP B 896 GLY B 955	None	1.15A	5hesB-3qd2B: 21.5	5hesB-3qd2B: 25.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	ALA B 616 LYS B 618 GLU B 635 LEU B 639 CYH B 889 GLY B 952	None	0.75A	5hi2A-3qd2B: 22.2	5hi2A-3qd2B: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	ALA B 616 LYS B 618 LEU B 639 CYH B 889 HIS B 933 GLY B 952	None	0.82A	5hi2A-3qd2B: 22.2	5hi2A-3qd2B: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 616 LYS B 618 ILE B 884 PHE B 942 GLY B 952	None	0.61A	5hieA-3qd2B: 21.5	5hieA-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	GLY B 599 ALA B 616 LYS B 618 PHE B 942 GLY B 952	None	0.52A	5hieA-3qd2B: 21.5	5hieA-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	GLY B 599 VAL B 603 ALA B 616 PHE B 942 GLY B 952	None	0.58A	5hieA-3qd2B: 21.5	5hieA-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	VAL B 603 ALA B 616 ILE B 884 PHE B 942 GLY B 952	None	0.68A	5hieA-3qd2B: 21.5	5hieA-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 616 LYS B 618 ILE B 884 PHE B 942 GLY B 952	None	0.63A	5hieB-3qd2B: 21.6	5hieB-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	GLY B 599 ALA B 616 LYS B 618 PHE B 942 GLY B 952	None	0.54A	5hieB-3qd2B: 21.6	5hieB-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	GLY B 599 VAL B 603 ALA B 616 PHE B 942 GLY B 952	None	0.59A	5hieB-3qd2B: 21.6	5hieB-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	VAL B 603 ALA B 616 ILE B 884 PHE B 942 GLY B 952	None	0.69A	5hieB-3qd2B: 21.6	5hieB-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	GLY B 596 ALA B 616 LYS B 618 PHE B 942 GLY B 952 ASP B 953	None	0.87A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	GLY B 596 VAL B 603 ALA B 616 PHE B 942 GLY B 952 ASP B 953	None	0.83A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	GLY B 599 ALA B 616 LYS B 618 PHE B 942 GLY B 952 ASP B 953	None	0.55A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	6 / 12	GLY B 599 VAL B 603 ALA B 616 PHE B 942 GLY B 952 ASP B 953	None	0.63A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 616 LYS B 618 ILE B 884 PHE B 942 GLY B 952	None	0.60A	5hieD-3qd2B: 21.9	5hieD-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	GLY B 599 ALA B 616 LYS B 618 PHE B 942 GLY B 952	None	0.51A	5hieD-3qd2B: 21.9	5hieD-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	GLY B 599 VAL B 603 ALA B 616 PHE B 942 GLY B 952	None	0.58A	5hieD-3qd2B: 21.9	5hieD-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	VAL B 603 ALA B 616 ILE B 884 PHE B 942 GLY B 952	None	0.68A	5hieD-3qd2B: 21.9	5hieD-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I6X_A_8PRA705_1 (SODIUM-DEPENDENT SEROTONIN TRANSPORTER)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 10	ASP B1004 ILE B1069 PHE B 916 SER B1007 GLY B1009	None	1.18A	5i6xA-3qd2B: undetectable	5i6xA-3qd2B: 20.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 8	ALA B 616 GLU B 635 CYH B 889 ASP B 953	None	0.46A	5owrA-3qd2B: 20.4	5owrA-3qd2B: 25.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_2 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	4 / 5	VAL B 603 LEU B 888 CYH B 889 ASP B 953	None	0.72A	5vcvA-3qd2B: 19.9	5vcvA-3qd2B: 25.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5X23_A_LSNA502_1 (CYTOCHROME P450 2C9)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 638 VAL B 951 ALA B 922 LEU B1008 LEU B 936	None	1.06A	5x23A-3qd2B: undetectable	5x23A-3qd2B: 20.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XXI_A_LSNA501_1 (CYTOCHROME P450 2C9)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	ALA B 638 VAL B 951 ALA B 922 LEU B1008 LEU B 936	None	1.08A	5xxiA-3qd2B: undetectable	5xxiA-3qd2B: 20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6N91_B_DCFB401_0 (ADENOSINE DEAMINASE)	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	5 / 12	LEU B1008 LEU B 936 ILE B 647 ALA B 922 HIS B 927	None	1.30A	6n91B-3qd2B: undetectable	6n91B-3qd2B: 12.84

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1MOG_A_RBFA200_1","DODECIN","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",3,"PHE B 589;TRP B 654;GLU B 656","None","1.12A","1mogA-3qd2B:undetectable","1mogA-3qd2B:13.73"],["1T03_P_TFOP822_1","POL POLYPROTEIN;SYNTHETIC OLIGONUCLEOTIDE PRIMER","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"MET B 945;ASP B 946;ASP B 947;HIS B 914","None","1.39A","1t03A-3qd2B:undetectable","1t03A-3qd2B:20.98"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"ALA B 616;GLU B 635;LEU B 639;CYH B 889;HIS B 933;GLY B 952","None","0.77A","1uwhA-3qd2B:21.8","1uwhA-3qd2B:27.01"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"ALA B 616;GLU B 635;LEU B 639;HIS B 933;GLY B 952;PHE B 942","None","1.42A","1uwhA-3qd2B:21.8","1uwhA-3qd2B:27.01"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"ALA B 616;LYS B 618;GLU B 635;LEU B 639;CYH B 889;HIS B 933;GLY B 952","None","0.76A","1uwhB-3qd2B:21.7","1uwhB-3qd2B:27.01"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;GLU B 635;CYH B 889;HIS B 933;GLY B 952","None","0.76A","1uwjA-3qd2B:21.5","1uwjA-3qd2B:25.35"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;GLU B 635;CYH B 889;HIS B 933;GLY B 952","None","0.75A","1uwjB-3qd2B:21.6","1uwjB-3qd2B:25.35"],["1XDK_B_9CRB600_1","RETINOIC ACID RECEPTOR, BETA","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 922;LEU B1008;ILE B1069;ILE B1070;LEU B 936","None","1.20A","1xdkB-3qd2B:undetectable","1xdkB-3qd2B:21.29"],["2HC4_A_VDXA525_2","VITAMIN D RECEPTOR","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"LEU B1015;LEU B1012;ILE B1005;ARG B1063","None","1.14A","2hc4A-3qd2B:undetectable","2hc4A-3qd2B:23.94"],["2J9D_A_ACTA1117_0","HYPOTHETICAL NITROGEN REGULATORY PII-LIKE PROTEIN MJ0059","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",3,"ASP B 906;ARG B 907;ARG B 901","None","1.10A","2j9dA-3qd2B:2.7;2j9dC-3qd2B:undetectable","2j9dA-3qd2B:19.02;2j9dC-3qd2B:19.02"],["2VAV_F_CSCF1383_2","ACETYL-COA--DEACETYLCEPHALOSPORIN C ACETYLTRANSFERASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",3,"LEU B 894;MET B 898;MET B 595","None","0.95A","2vavF-3qd2B:2.7","2vavF-3qd2B:20.99"],["2XYT_D_TC9D1206_2","SOLUBLE ACETYLCHOLINE RECEPTOR;SOLUBLE ACETYLCHOLINE RECEPTOR","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"TYR B 883;GLN B 885;ILE B 617;SER B 583","None","1.01A","2xytE-3qd2B:undetectable","2xytE-3qd2B:21.35"],["2XYT_G_TC9G1206_2","SOLUBLE ACETYLCHOLINE RECEPTOR;SOLUBLE ACETYLCHOLINE RECEPTOR","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"TYR B 883;GLN B 885;ILE B 617;SER B 583","None","1.05A","2xytH-3qd2B:undetectable","2xytH-3qd2B:21.35"],["2XYT_H_TC9H1206_2","SOLUBLE ACETYLCHOLINE RECEPTOR;SOLUBLE ACETYLCHOLINE RECEPTOR","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"TYR B 883;GLN B 885;ILE B 617;SER B 583","None","1.04A","2xytI-3qd2B:undetectable","2xytI-3qd2B:21.35"],["3HEC_A_STIA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 616;LYS B 618;GLU B 635;LEU B 639;LEU B 888","None","0.52A","3hecA-3qd2B:21.1","3hecA-3qd2B:25.32"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"VAL B 603;LYS B 618;VAL B 648;ILE B 884","None","0.70A","3mssD-3qd2B:21.3","3mssD-3qd2B:24.03"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 955","None","0.90A","3og7A-3qd2B:22.3","3og7A-3qd2B:26.92"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;PHE B 954","None","0.77A","3og7A-3qd2B:22.3","3og7A-3qd2B:26.92"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;LYS B 618;LEU B 639;PHE B 942;PHE B 954","None","0.89A","3og7A-3qd2B:22.3","3og7A-3qd2B:26.92"],["4I41_A_MIXA500_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"VAL B 603;ALA B 616;ASP B 896;ASP B 935;LYS B 937;ASN B 940;ASP B 953","None","0.70A","4i41A-3qd2B:24.9","4i41A-3qd2B:25.88"],["4IK6_B_LURB201_1","TRANSTHYRETIN","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"MET B 886;LEU B 882;ALA B 653;LEU B 655","None","0.82A","4ik6B-3qd2B:undetectable","4ik6B-3qd2B:18.59"],["4OJB_A_198A1001_2","ANDROGEN RECEPTOR","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"LEU B1012;ILE B1028;ILE B1029;VAL B1032","None","0.78A","4ojbA-3qd2B:undetectable","4ojbA-3qd2B:22.32"],["4QMS_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"ALA B 616;LYS B 618;GLU B 635;ILE B 884;MET B 886;ASP B 953","None","0.75A","4qmsA-3qd2B:25.8","4qmsA-3qd2B:24.79"],["4QOP_D_HQED503_1","CATALASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ILE B 617;PRO B 591;GLN B 885;TYR B 615;ASP B 611","None","1.46A","4qopD-3qd2B:0.0","4qopD-3qd2B:18.46"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;LYS B 618;GLU B 635;CYH B 889;GLY B 952","None","0.78A","4r7iA-3qd2B:20.5","4r7iA-3qd2B:25.25"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 616;LYS B 618;ILE B 884;PHE B 942;GLY B 952","None","0.52A","4rzvA-3qd2B:22.3","4rzvA-3qd2B:25.28"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 616;LYS B 618;PHE B 942;GLY B 952;PHE B 954","None","0.91A","4rzvA-3qd2B:22.3","4rzvA-3qd2B:25.28"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 952;GLY B 955","None","1.26A","4rzvB-3qd2B:22.3","4rzvB-3qd2B:25.28"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 952;PHE B 954","None","1.02A","4rzvB-3qd2B:22.3","4rzvB-3qd2B:25.28"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 952;ASP B 953;PHE B 954","None","0.71A","4xv2A-3qd2B:22.7","4xv2A-3qd2B:24.52"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"VAL B 603;ALA B 616;CYH B 889;PHE B 942;GLY B 952;ASP B 953;PHE B 954","None","0.75A","4xv2A-3qd2B:22.7","4xv2A-3qd2B:24.52"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 952;ASP B 953;PHE B 954","None","0.70A","4xv2B-3qd2B:22.7","4xv2B-3qd2B:24.52"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"ALA B 616;LYS B 618;LEU B 639;PHE B 942;GLY B 952;ASP B 953;PHE B 954","None","0.83A","4xv2B-3qd2B:22.7","4xv2B-3qd2B:24.52"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 952;PHE B 954","None","0.81A","5cswA-3qd2B:22.4","5cswA-3qd2B:24.93"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;LYS B 618;LEU B 639;PHE B 942;PHE B 954","None","0.98A","5cswA-3qd2B:22.4","5cswA-3qd2B:24.93"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",7,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 952;PHE B 954","None","0.84A","5cswB-3qd2B:22.4","5cswB-3qd2B:24.93"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;ILE B 884;LEU B 888;GLY B 952;ASP B 953","None","0.69A","5h2uB-3qd2B:16.1","5h2uB-3qd2B:25.75"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;ILE B 884;LEU B 888;GLY B 952;ASP B 953","None","0.66A","5h2uD-3qd2B:21.8","5h2uD-3qd2B:25.75"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"VAL B 603;ALA B 616;LYS B 618;ILE B 884;ASP B 896;GLY B 955","None","1.15A","5hesB-3qd2B:21.5","5hesB-3qd2B:25.20"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"ALA B 616;LYS B 618;GLU B 635;LEU B 639;CYH B 889;GLY B 952","None","0.75A","5hi2A-3qd2B:22.2","5hi2A-3qd2B:25.63"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"ALA B 616;LYS B 618;LEU B 639;CYH B 889;HIS B 933;GLY B 952","None","0.82A","5hi2A-3qd2B:22.2","5hi2A-3qd2B:25.63"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 616;LYS B 618;ILE B 884;PHE B 942;GLY B 952","None","0.61A","5hieA-3qd2B:21.5","5hieA-3qd2B:26.13"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"GLY B 599;ALA B 616;LYS B 618;PHE B 942;GLY B 952","None","0.52A","5hieA-3qd2B:21.5","5hieA-3qd2B:26.13"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"GLY B 599;VAL B 603;ALA B 616;PHE B 942;GLY B 952","None","0.58A","5hieA-3qd2B:21.5","5hieA-3qd2B:26.13"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"VAL B 603;ALA B 616;ILE B 884;PHE B 942;GLY B 952","None","0.68A","5hieA-3qd2B:21.5","5hieA-3qd2B:26.13"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 616;LYS B 618;ILE B 884;PHE B 942;GLY B 952","None","0.63A","5hieB-3qd2B:21.6","5hieB-3qd2B:26.13"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"GLY B 599;ALA B 616;LYS B 618;PHE B 942;GLY B 952","None","0.54A","5hieB-3qd2B:21.6","5hieB-3qd2B:26.13"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"GLY B 599;VAL B 603;ALA B 616;PHE B 942;GLY B 952","None","0.59A","5hieB-3qd2B:21.6","5hieB-3qd2B:26.13"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"VAL B 603;ALA B 616;ILE B 884;PHE B 942;GLY B 952","None","0.69A","5hieB-3qd2B:21.6","5hieB-3qd2B:26.13"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"GLY B 596;ALA B 616;LYS B 618;PHE B 942;GLY B 952;ASP B 953","None","0.87A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"GLY B 596;VAL B 603;ALA B 616;PHE B 942;GLY B 952;ASP B 953","None","0.83A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"GLY B 599;ALA B 616;LYS B 618;PHE B 942;GLY B 952;ASP B 953","None","0.55A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",6,"GLY B 599;VAL B 603;ALA B 616;PHE B 942;GLY B 952;ASP B 953","None","0.63A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 616;LYS B 618;ILE B 884;PHE B 942;GLY B 952","None","0.60A","5hieD-3qd2B:21.9","5hieD-3qd2B:26.13"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"GLY B 599;ALA B 616;LYS B 618;PHE B 942;GLY B 952","None","0.51A","5hieD-3qd2B:21.9","5hieD-3qd2B:26.13"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"GLY B 599;VAL B 603;ALA B 616;PHE B 942;GLY B 952","None","0.58A","5hieD-3qd2B:21.9","5hieD-3qd2B:26.13"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"VAL B 603;ALA B 616;ILE B 884;PHE B 942;GLY B 952","None","0.68A","5hieD-3qd2B:21.9","5hieD-3qd2B:26.13"],["5I6X_A_8PRA705_1","SODIUM-DEPENDENT SEROTONIN TRANSPORTER","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ASP B1004;ILE B1069;PHE B 916;SER B1007;GLY B1009","None","1.18A","5i6xA-3qd2B:undetectable","5i6xA-3qd2B:20.25"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"ALA B 616;GLU B 635;CYH B 889;ASP B 953","None","0.46A","5owrA-3qd2B:20.4","5owrA-3qd2B:25.20"],["5VCV_A_1N1A404_2","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",4,"VAL B 603;LEU B 888;CYH B 889;ASP B 953","None","0.72A","5vcvA-3qd2B:19.9","5vcvA-3qd2B:25.49"],["5X23_A_LSNA502_1","CYTOCHROME P450 2C9","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 638;VAL B 951;ALA B 922;LEU B1008;LEU B 936","None","1.06A","5x23A-3qd2B:undetectable","5x23A-3qd2B:20.08"],["5XXI_A_LSNA501_1","CYTOCHROME P450 2C9","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"ALA B 638;VAL B 951;ALA B 922;LEU B1008;LEU B 936","None","1.08A","5xxiA-3qd2B:undetectable","5xxiA-3qd2B:20.00"],["6N91_B_DCFB401_0","ADENOSINE DEAMINASE","3qd2","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Mus musculus",5,"LEU B1008;LEU B 936;ILE B 647;ALA B 922;HIS B 927","None","1.30A","6n91B-3qd2B:undetectable","6n91B-3qd2B:12.84"]]